ORAMED PHARMACEUTICALS INC. — Income Charts
9 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+49.3% +$660K
$2M
Cost of Revenue
$2M
Gross Profit
$13K
R&D↓-28.9% -$3M
$6M
D&A↓-38.3% -$75K
$121K
Operating Income↑+4.3% +$681K
$-15M
EBITDA↑+3.9% +$606K
$-15M
Interest Expense
$853K
Interest Income
$10K
Other Income/Expense↑+295.1% +$68M
$90M
Pretax Income↑+1380.4% +$70M
$75M
Tax Provision
$11M
Net Income↑+1158.8% +$59M
$64M
Gross Margin
0.7%
Operating Margin↑+422.4pts
-754.4%
Net Margin↑+2822.8pts
3202.5%
Effective Tax Rate
15.0%
Deferred Tax Liabilities
$8M
DTA Valuation Allowance↓-0.3% -$90K
$28M
NOL Carryforwards↑+709.3% +$24M
$27M
ETR (Continuing Operations)
15.0%
ETR Federal Statutory↑+0.0pts
21.0%
Operating Lease Cost↑+9.4% +$25K
$292K
Revenue YoY Variation↓-50.7pts
-50.4%
Income YoY Variation↑+41.5pts
61.2%